GlassScriptPhysician profile
Michael J Greenblatt
NPI 1619066099
$11,873.95
in general payments reported to CMS, 2019-2025
33 companies · $1,494 in 2025
The $1,494 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $503 · 2020: $269 · 2021: $6,568 · 2022: $473 · 2023: $1,134 · 2024: $1,432 · 2025: $1,494.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,060.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,060.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $6,657.59 | 2019-2021 | |
| Abbvie INC. | $1,134.98 | 2022-2025 | |
| Glaxosmithkline, LLC. | $1,095.07 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $489.86 | 2019-2025 | |
| Novo Nordisk INC | $424.49 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Exact Sciences Corporation | $318.84 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $315.43 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $222.02 | 2019-2025 | Evenity, Prolia, Otezla |
| Abbott Laboratories | $169.63 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Astrazeneca Pharmaceuticals LP | $164.56 | 2020-2025 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $119.15 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $114.67 | 2019-2025 | Eliquis, Camzyos |
| Sumitomo Pharma America, INC. | $71.81 | 2023-2025 | Gemtesa |
| Merck Sharp & Dohme LLC | $62.27 | 2020-2024 | Belsomra, Steglatro, Gardasil |
| Janssen Pharmaceuticals, INC | $60.73 | 2019-2020 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $59.89 | 2019-2023 | Trintellix |
| Astellas Pharma US INC | $46.85 | 2024-2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.66 | 2022-2023 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $36.67 | 2024 | |
| Gilead Sciences, INC. | $35.31 | 2022-2023 | |
| Optinose US, INC. | $28.12 | 2025 | |
| Lundbeck LLC | $26.15 | 2025 | Rexulti |
| Idorsia Pharmaceuticals US INC | $22.65 | 2023 | Quviviq |
| Novartis Pharmaceuticals Corporation | $20.62 | 2024 | |
| Averitas Pharma INC. | $17.48 | 2024 | Qutenza |
| Ars Pharmaceuticals Operations, INC. | $17.19 | 2025 | Neffy |
| Verona Pharma, INC. | $17.04 | 2025 | Ohtuvayre |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.95 | 2025 | Caplyta |
| Alnylam Pharmaceuticals INC. | $16.83 | 2024 | Givlaari |
| Daiichi Sankyo INC. | $15.61 | 2024 | Injectafer |
| Dexcom, INC. | $14.81 | 2025 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $12.16 | 2019 | |
| Sanofi Pasteur INC. | $10.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Greenblatt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.